Non Small Cell Lung CancerPhase 1/2NCT06868849
A Study of JMT203 in Patients With Cancer Cachexia
A Phase 1/2 study testing JMT203 Injection in people with Non Small Cell Lung Cancer and Pancreatic Cancer, run by Shanghai JMT-Bio Inc. at 1 site in China.
Trial summary
A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia
- What is being tested?
- JMT203 Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 307 participants
- Where
- 1 siteChina
- Study dates
- 15 May 2024to 15 May 2029
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years old;
- Voluntarily participate in the study and sign the informed consent form;
- Age ≥ 18 years old;
- Voluntarily participate in the study and sign the informed consent form;
- Malignant solid tumors confirmed histologically or cytologically, with ongoing or completed anti-tumor treatment, and no significant tumor progression within 28 days prior to the first drug administration，and the investigator estimates that the participant will not require a switch to another anticancer therapy due to disease progression during the first treatment cycle (21 days). For the Phase II portion:
- Cohort A (participants with colorectal cancer cachexia): Must meet the following treatment status: currently receiving or about to initiate investigator-selected second-line standard anticancer therapy, with no more than 5 cycles of second-line therapy, and not suitable for immune checkpoint inhibitors.;
Show all 14Show fewer
- Cohort B (participants with pancreatic cancer cachexia): Must meet the following treatment status: currently receiving or about to initiate investigator-selected first-line standard anticancer therapy, with no more than 3 cycles of first-line therapy, and not suitable for targeted therapy.;
- Cohort C (participants with cachexia from other solid tumors): Currently receiving or have completed investigator-selected standard anticancer therapy, with no more than three prior lines of therapy.
- Diagnosed with cancer cachexia according to the criteria of the 2011 International Consensus on Cancer Cachexia: Definition and Classification, combined with characteristics of the Chinese population, i.e., presenting with one of the following within 6 months (previous weight data must be supported by written documentation approved by the sponsor): involuntary weight loss >5%, or weight loss >2% when Body Mass Index （BMI） <18.5 kg/m²;
- Adequate organ function, meeting relevant laboratory test standards （without transfusion or hematopoietic growth factor support within 14 days prior to testing）:
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: ≤1;
- 7. Eastern Cooperative Oncology Group Performance Status （ECOG PS）score: ≤2;
- Estimated survival ≥4 months;
- Fertile eligible patients must use adequate contraceptive measures from the time of signing the informed consent form until 6 months after the last drug administration; female patients of childbearing age must have a negative serum pregnancy test within 7 days before the first drug administration.
Who cannot join
- Presence of reversible causes leading to decreased food intake;
- Patients with dysphagia or poor food digestion and absorption, including gastrointestinal obstruction, active inflammatory bowel disease, or short bowel syndrome;
- Patients with cachexia caused by clearly identified other causes, such as severe chronic obstructive pulmonary disease, uncontrolled thyroid disease, vital organ failure, or Acquired Immune Deficiency Syndrome （AIDS）;
- Patients receiving tube feeding or parenteral nutrition therapy during the screening period;
- Patients who have taken any prescription medications for appetite enhancement or improve weight loss within 28 days or 5 half-lives (whichever is shorter) before the first study drug administration, including but not limited to anamorelin, medroxyprogesterone acetate, dronabinol, medical marijuana, etc.;
- Initiation of systemic glucocorticoids (prednisone >10 mg/day or equivalent doses of other similar drugs) or other immunosuppressive therapies within 28 days before the first study drug administration, excluding pretreatment for antitumor therapy;
Show all 22Show fewer
- Patients with a BMI exceeding 30 kg/m²;
- Patients who have undergone major surgery within 4 weeks before the first study drug administration and have not recovered, or are expected to undergo major surgery during the study;
- Patients who have received other clinical study medications within 4 weeks or 5 half-lives (whichever is shorter) before the first study drug administration;
- Patients with severe infections requiring intravenous antibiotics, antivirals, or antifungals during the screening period;
- Patients with difficult-to-control moderate to large amounts of serous cavity effusion, such as pericardial effusion or pleural/abdominal/pelvic effusion, within 14 days before the first study drug administration;
- Patients with a second primary active malignancy within 2 years before the first study drug administration, excluding locally curable tumors that have undergone radical treatment (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, breast carcinoma in situ);
- Patients with active central nervous system metastases (brain metastases, carcinomatous meningitis, and spinal cord metastases), except for those with controlled lesions confirmed by imaging studies within 28 days before the first use of the investigational product;
- History of severe cardiovascular disease, including but not limited to:
- Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second- or third-degree atrioventricular block, etc.;
- Occurrence of acute coronary syndrome, congestive heart failure, stroke, or other cardiovascular events of grade 3 or higher within 6 months before the first study drug administration;
- New York Heart Association functional class ≥III or left ventricular ejection fraction (LVEF) <50%;
- Patients with severe immune deficiency or a history of organ transplantation;
- Patients with recent (within the past year) or current depression or suicidal ideation/tendencies;
- Known allergy to JMT203 or its components;
- History of severe allergic reactions or uncontrollable allergic asthma;
- Patients deemed unsuitable for participation in this clinical study by the investigator for other reasons.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Sir run run shaw Hospital
Zhejiang
Sir run run shaw Hospital
About this study
Official title: A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients With Cancer Cachexia
A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
Read the detailed description
This is a study of JMT203 in patients with cancer cachexia, comprising two parts: Phase Ia, which involves a dose-escalation and dose-expansion study of JMT203 in patients with cancer cachexia, and Phase II, which is a multicenter, randomized, double-blind, placebo-controlled clinical study. The phase II stage includes three cohorts: Cohort A (participants with colorectal cancer cachexia), Cohort B (participants with pancreatic cancer cachexia), and Cohort C (participants with cachexia from other solid tumors) . The primary objectives of Phase Ia are to assess the safety/tolerability of JMT203 in patients with cancer cachexia and to determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose for expansion (RDE) of JMT203. In Phase II, the primary objectives include evaluating the preliminary efficacy of JMT203 at doses of 50 mg and 150 mg versus placebo over a 12-week treatment period and determining the recommended Phase 3 dose (RP3D) of JMT203.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia, Pancreatic Cancer Cachexia
- Being tested
- JMT203 Injection
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JMT203 InjectionDrug
Drug：JMT203 Injection
- Anti-GFRAL monoclonal antibody
- Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1).
JMT203 InjectionDrug
Drug：JMT203 Injection
- Anti-GFRAL monoclonal antibody
- Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1).
| Study group | Role | What they receive |
|---|---|---|
| Experimental: Dose Escalation, Dose Expansion Phase | Experimental | Dose escalation (Phase Ia) - Five dose levels of JMT203 will be tested in patients with cancer cachexia according to an accelerated titration design combined with a "3+3" dose escalation scheme. If the highest predefined dose group demonstrates good safety and tolerability during dose escalation, further discussion will be held on whether to proceed to a higher dose group or to explore doses between two existing groups.
Dose expansion (Phase Ia) - Based on pharmacokinetics (PK), preliminary efficacy, and safety data, 1 to 3 dose levels that are potentially effective will be selected.
Cohort expansion- One to three potentially effective dose groups will be selected for expansion based on PK, preliminary efficacy, and safety data, with a maximum of 24 participants per group in principle (including participants from the same dose group in the dose-escalation phase). Receives: Drug: JMT203 Injection |
| Experimental: JMT203 50 mg | Experimental | Double blind phase (Phase II)：JMT203 50 mg administered subcutaneously every 3 weeks over a 12-week treatment period. Receives: Drug: JMT203 Injection |
| Experimental: JMT203 150 mg | Experimental | Double blind phase (Phase II)：JMT203 150 mg administered subcutaneously every 3 weeks over a 12-week treatment period; Open-Label Treatment Phase (Phase II): JMT203 administered subcutaneously at 150 mg or at the RP3D (once established in this study) for up to 51 weeks. Receives: Drug: JMT203 Injection |
| Experimental: Placebo | Placebo comparator | Double blind phase (Phase II)：Placebo administered subcutaneously every 3 weeks over a 12-week treatment period; Receives: Drug: JMT203 Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
Measured: Up to 90 days after the last dose of JMT203
Phase Ia: Incidence of dose-limiting toxicity (DLT) events
Measured: Up to 21 days after the first dose of JMT203
Phase Ia: MTD (if applicable).
Measured: Up to 90 days post last dose
Phase Ia: RDE.
Measured: Up to 90 days post last dose
Phase Ib: Average change in body weight from baseline at each assessment timepoint within 12 weeks.
Measured: Within 12 weeks from baseline
Phase II: RP3D
Measured: Approximately 1 year from baseline
Secondary outcomes (13)
Phase Ia: Area under the curve from time "0" to the time of the last measurable concentration (AUC0-t) of JMT203
Measured: Up to 90 days after the last dose of JMT203
Phase Ia: Maximum measured plasma concentration (Cmax) of JMT203
Measured: Up to 90 days after the last dose of JMT203
Phase Ia: Time when Cmax occurred (Tmax) of JMT203
Measured: Up to 90 days after the last dose of JMT203
Phase Ia: Incidence of anti-drug antibodies (ADA).
Measured: Up to 90 days after the last dose of JMT203
Phase Ia: Average change in body weight from baseline at each assessment timepoint within 12 weeks.
Measured: Within 12 weeks from baseline
Phase II: Average change in the skeletal muscle index (SMI) of the third lumbar vertebra, measured by computed tomography (CT), from baseline to 12 weeks.
Measured: Within 12 weeks from baseline
Phase II: Average change in the severity of anorexia (based on the Functional Assessment of Anorexia/Cachexia Therapy - Anorexia/Cachexia Subscale [FAACT-A/CS]) from baseline to each assessment timepoint.
Measured: Within 12 weeks from baseline
Phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
Measured: Up to 90 days after the last dose of JMT203
Phase II: Blood concentration of JMT203;
Measured: Up to 90 days after the last dose of JMT203
PhaseII: Incidence of ADA.
Measured: Up to 90 days after the last dose of JMT203
PhaseII: Objective Response Rate （ORR）
Measured: Approximately 12 weeks from baseline
PhaseII: Progression-Free Survival (PFS)
Measured: Approximately 1 year from baseline
Phase II: overall survival (OS).
Measured: Approximately up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2025
- Study start15 May 2024
- Primary completion14 Aug 2027 (estimated)
- Study completion15 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Shanghai JMT-Bio Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- There is no comparison group.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 307 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai JMT-Bio Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06868849
- Sponsor's protocol ID
- JMT203-001
- Status last verified
- May 2026
- First submitted
- 18 Feb 2025
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients With Cancer Cachexia
- ClinicalTrials.gov ID
- NCT06868849
- Acronym / sponsor ID
- JMT203-001
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia, Pancreatic Cancer Cachexia
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 307 participants (estimated)
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry (pharma, biotech, devices)
- Study start
- 15 May 2024 (actual)
- Primary completion
- 14 Aug 2027 (estimated)
- Study completion
- 15 May 2029 (estimated)
- First posted
- 11 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
Detailed description
This is a study of JMT203 in patients with cancer cachexia, comprising two parts: Phase Ia, which involves a dose-escalation and dose-expansion study of JMT203 in patients with cancer cachexia, and Phase II, which is a multicenter, randomized, double-blind, placebo-controlled clinical study. The phase II stage includes three cohorts: Cohort A (participants with colorectal cancer cachexia), Cohort B (participants with pancreatic cancer cachexia), and Cohort C (participants with cachexia from other solid tumors) . The primary objectives of Phase Ia are to assess the safety/tolerability of JMT203 in patients with cancer cachexia and to determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose for expansion (RDE) of JMT203. In Phase II, the primary objectives include evaluating the preliminary efficacy of JMT203 at doses of 50 mg and 150 mg versus placebo over a 12-week treatment period and determining the recommended Phase 3 dose (RP3D) of JMT203.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- There is no comparison group.
| Arm | Type | Receives |
|---|---|---|
| Experimental: Dose Escalation, Dose Expansion Phase | Experimental | Drug: JMT203 InjectionDose escalation (Phase Ia) - Five dose levels of JMT203 will be tested in patients with cancer cachexia according to an accelerated titration design combined with a "3+3" dose escalation scheme. If the highest predefined dose group demonstrates good safety and tolerability during dose escalation, further discussion will be held on whether to proceed to a higher dose group or to explore doses between two existing groups. Dose expansion (Phase Ia) - Based on pharmacokinetics (PK), preliminary efficacy, and safety data, 1 to 3 dose levels that are potentially effective will be selected. Cohort expansion- One to three potentially effective dose groups will be selected for expansion based on PK, preliminary efficacy, and safety data, with a maximum of 24 participants per group in principle (including participants from the same dose group in the dose-escalation phase). |
| Experimental: JMT203 50 mg | Experimental | Drug: JMT203 InjectionDouble blind phase (Phase II)：JMT203 50 mg administered subcutaneously every 3 weeks over a 12-week treatment period. |
| Experimental: JMT203 150 mg | Experimental | Drug: JMT203 InjectionDouble blind phase (Phase II)：JMT203 150 mg administered subcutaneously every 3 weeks over a 12-week treatment period; Open-Label Treatment Phase (Phase II): JMT203 administered subcutaneously at 150 mg or at the RP3D (once established in this study) for up to 51 weeks. |
| Experimental: Placebo | Placebo comparator | Drug: JMT203 InjectionDouble blind phase (Phase II)：Placebo administered subcutaneously every 3 weeks over a 12-week treatment period; |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Age ≥ 18 years old;
- Voluntarily participate in the study and sign the informed consent form;
- Age ≥ 18 years old;
- Voluntarily participate in the study and sign the informed consent form;
- Malignant solid tumors confirmed histologically or cytologically, with ongoing or completed anti-tumor treatment, and no significant tumor progression within 28 days prior to the first drug administration，and the investigator estimates that the participant will not require a switch to another anticancer therapy due to disease progression during the first treatment cycle (21 days). For the Phase II portion:
Key exclusion criteria (22 listed)
- Presence of reversible causes leading to decreased food intake;
- Patients with dysphagia or poor food digestion and absorption, including gastrointestinal obstruction, active inflammatory bowel disease, or short bowel syndrome;
- Patients with cachexia caused by clearly identified other causes, such as severe chronic obstructive pulmonary disease, uncontrolled thyroid disease, vital organ failure, or Acquired Immune Deficiency Syndrome （AIDS）;
- Patients receiving tube feeding or parenteral nutrition therapy during the screening period;
- Patients who have taken any prescription medications for appetite enhancement or improve weight loss within 28 days or 5 half-lives (whichever is shorter) before the first study drug administration, including but not limited to anamorelin, medroxyprogesterone acetate, dronabinol, medical marijuana, etc.;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| JMT203 InjectionDrug：JMT203 Injection * Anti-GFRAL monoclonal antibody * Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1). | Drug | Experimental: Dose Escalation, Dose Expansion Phase |
| JMT203 InjectionDrug：JMT203 Injection * Anti-GFRAL monoclonal antibody * Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1). | Drug | Experimental: JMT203 150 mg, Experimental: JMT203 50 mg, Experimental: Placebo |
Primary outcome
Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
Time frame: Up to 90 days after the last dose of JMT203
Phase Ia: Incidence of dose-limiting toxicity (DLT) events
Time frame: Up to 21 days after the first dose of JMT203
Phase Ia: MTD (if applicable).
Time frame: Up to 90 days post last dose
Phase Ia: RDE.
Time frame: Up to 90 days post last dose
Phase Ib: Average change in body weight from baseline at each assessment timepoint within 12 weeks.
Time frame: Within 12 weeks from baseline
Phase II: RP3D
Time frame: Approximately 1 year from baseline
13 secondary outcomes
Phase Ia: Area under the curve from time "0" to the time of the last measurable concentration (AUC0-t) of JMT203
Time frame: Up to 90 days after the last dose of JMT203
Phase Ia: Maximum measured plasma concentration (Cmax) of JMT203
Time frame: Up to 90 days after the last dose of JMT203
Phase Ia: Time when Cmax occurred (Tmax) of JMT203
Time frame: Up to 90 days after the last dose of JMT203
Phase Ia: Incidence of anti-drug antibodies (ADA).
Time frame: Up to 90 days after the last dose of JMT203
Phase Ia: Average change in body weight from baseline at each assessment timepoint within 12 weeks.
Time frame: Within 12 weeks from baseline
Phase II: Average change in the skeletal muscle index (SMI) of the third lumbar vertebra, measured by computed tomography (CT), from baseline to 12 weeks.
Time frame: Within 12 weeks from baseline
Phase II: Average change in the severity of anorexia (based on the Functional Assessment of Anorexia/Cachexia Therapy - Anorexia/Cachexia Subscale [FAACT-A/CS]) from baseline to each assessment timepoint.
Time frame: Within 12 weeks from baseline
Phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
Time frame: Up to 90 days after the last dose of JMT203
Phase II: Blood concentration of JMT203;
Time frame: Up to 90 days after the last dose of JMT203
PhaseII: Incidence of ADA.
Time frame: Up to 90 days after the last dose of JMT203
PhaseII: Objective Response Rate （ORR）
Time frame: Approximately 12 weeks from baseline
PhaseII: Progression-Free Survival (PFS)
Time frame: Approximately 1 year from baseline
Phase II: overall survival (OS).
Time frame: Approximately up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing JMT203 Injection in people with Non Small Cell Lung Cancer and Pancreatic Cancer, run by Shanghai JMT-Bio Inc. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Trials Information Group Officer (86-0311-69085587, ctr-contact@cspc.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs). (time frame: Up to 90 days after the last dose of JMT203). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.